How We Can Help

Eligibility Criteria

Update your billing and coding systems to include the permanent CYRAMZA® (ramucirumab) J-code: J9308, injection, ramucirumab, 5 mg. Issued by the Centers for Medicare & Medicaid Services (CMS), this permanent J-code is effective as of January 1, 2016.

How We Can Help

Eligibility Criteria

See if your patient qualifies for Lilly PatientOne services.

To enroll in Lilly PatientOne services, your patients will need to meet some basic requirements.

For reimbursement assistance:

  • A qualified Lilly Oncology drug must be administered in the United States
  • Patient must have proof of permanent, legal residency in the United States or Puerto Rico

For co-pay assistance*:

  • Patient is age 18 years or older
  • Patient must have proof of residency in the United States or Puerto Rico
  • Patient must be treated with ALIMTA® (pemetrexed for injection), CYRAMZA® (ramucirumab), ERBITUX® (cetuximab), LARTRUVO (olaratumab), or Portrazza® (necitumumab) for an FDA-approved indication
  • Patient must be commercially insured

This offer is invalid for patients whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program.

For the Lilly Cares Foundation:

  • Patient meets the requirements listed above
  • Patient has no medical insurance or his/her insurance does not cover therapy. If insured, patient must have been denied coverage after two rounds of appeals
  • Patient income is at or below 500% of the federal poverty level
  • Patient is in ongoing therapy
  • The date of service is within 180 days of the application approval
  • Treatment is or will be provided in an outpatient setting (provider is community-based billing on CMS-1500 or outpatient-facility billing on UB-04)

If you have questions about patient eligibility requirements, Lilly PatientOne program specialists are available Monday–Friday, 9 am–7 pm ET. Call 1-866-4PatOne (1-866-472-8663) and let us know what we can do to help.

This offer is not valid with any other financial support program, discount, or incentive involving ALIMTA, CYRAMZA, ERBITUX, LARTRUVO, or Portrazza.

† This offer is invalid for patients whose prescription claims for ALIMTA, CYRAMZA, ERBITUX, LARTRUVO, or Portrazza are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medigap, CHAMPUS, DOD, VA, TRICARE, or any state, patient, or pharmaceutical assistance program. Additional program restrictions apply. Please see full Terms and Conditions.

‡ Federal poverty level depends on family size.